Interleukin 10 is not essential for survival or for modulating T-cell function after injury

Surgery

Volumn 126, Issue 2, 1999, Pages 456-462

  Kavanagh, Eamon K ^a   Kell, Malcolm R ^a   Goebel, Andreas ^a   Soberg, Christopher C ^a   Mannick, John A ^a   Lederer, James A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BURN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SPLEEN CELL; T LYMPHOCYTE;

EID: 0032837740     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70192-3     Document Type: Article

References (24)

1. 1. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547-50.
2. 2. Howard M, Muchamel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205-8.
3. 3. Mulligan MS, Jones ML, Vaporciyan AA, Howard MC, Ward PA. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol 1993;151:5666-74.
4. 4. Van der Poll T, Marchant A, Buurman WA, Berman L, Keogh CV, Lazarus DD, et al. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995;155:5397-401.
5. 5. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of marophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995;155:2222-9.
6. 6. Engles RE, Huber TS, Zander DS, Hess PJ, Welborn MB, Moldawer LL, et al. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res 1997;69:425-8.
7. 7. Greenberger M, Strieter RM, Kunkel SL, Danforth J, Goodman R, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-9.
8. 8. Van der Poll T, Marchant A, Keogh C, Goldman M, Lowry S. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
9. 9. Kelly JL, Lyons A, Soberg CC, Mannick JA, Lederer JA. Anti-IL-10 antibody restores burn induced defects in T cell function. Surgery 1997;122:246-52.
10. 10. Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 1997;226:450-60.
11. 11. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-9.
12. 12. Kelly JL, O'Sullivan C, O'Riordain M, O'Riordain D, Lyons A, Doherty J, et al. Is circulating endotoxin the trigger for the systemic inflammatory response syndrome seen after injury? Ann Surg 1997;225:530-43.
13. 13. Oswald I, Wynn T, Sher A. Interleukin 10 inhibits macrophage microbicidal activity by blocking endogenous production of tumor necrosis factorα required as a costimulatory factor for interferonγ-induced activation. Proc Natl Acad Sci 1992;89:8676-80.
14. 14. Cassatella M, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993;178:2207-11.
15. 15. Bone RC. Toward an epidemiology and natural history of SIRS (Systemic Inflammatory Response Syndrome). JAMA 1992;268:3452-5.
16. 16. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/-mice: an overview. J Leukoc Biol 1997;61:389-96.
17. 17. Faunce DE, Gregory MS, Kovacs EJ. Acute ethanol exposure prior to thermal injury results in decreased T-cell responses mediated in part by increased production of IL-6. Shock 1998;10:135-40.
18. 18. Ueyama M, Maruyama I, Osame M, Sawada Y. Marked increase in plasma interleukin-6 in burn patients. J Lab Clin Med 1992;120:693-8.
19. 19. Polo M, Ko F, Busillo F, Cruse CW, Krizek TJ, Robson MC. Cytokine production in patients with hypertrophic burn scars. J Burn Care Rehabil 1997;18:477-82.
20. 20. Ayala A, Knotts JB, Ertel W, Perrin MM, Morrison MH, Chaudry IH. Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg 1993;128:89-95.
21. 21. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
22. 22. Gilbert KM, Hoang KD, Weigle WO. Th1 and Th2 clones differ in their response to a tolerogenic signal. J Immunol 1990;144:2063-71.
23. 23. Finkelman FD, Svetic A, Gresser I, Snapper C, Holmes J, Trotta PP, et al. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991;1:1179-88.
24. 24. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-84.